Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? ProShares UltraPro Short QQQ ETF trades at $37.32 (market cap $2.13B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.3× ProShares UltraPro Short QQQ ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro Short QQQ ETF for 12 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SQQQ | TVTX | |
|---|---|---|
Market Cap | $2.13B | $4.88B |
Volume | 37,167,173 | 1,668,577 |
Sector | Leveraged / Inverse | Health |
52-Week High | $89.43 | $67.52 |
52-Week Low | $31.83 | $26.79 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.98, up 1.04% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. As a 3x leveraged inverse ETF, its performance is directly tied to declines in the Nasdaq-100 index. Recent news highlights its use as a hedging tool against tech sector weakness, with articles discussing its potential benefits amid concerns over the AI-fueled tech rally.
The outlook for SQQQ is inherently tied to market sentiment toward the Nasdaq-100. It presents a high-risk, tactical opportunity for investors seeking to profit from or hedge against a downturn in major technology stocks. Key risks include the daily reset mechanism of leveraged ETFs, which can lead to decay in volatile markets, and the potential for rapid losses if the tech rally resumes.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
